Investment Analysts’ Recent Ratings Changes for Ardelyx (ARDX)

A number of research firms have changed their ratings and price targets for Ardelyx (NASDAQ: ARDX):

• 11/4/2025 – Ardelyx had its price target raised by analysts at Piper Sandler from $9.00 to $10.00. They now have a “neutral” rating on the stock.
• 11/3/2025 – Ardelyx had its price target raised by analysts at Citigroup Inc. from $10.00 to $11.00. They now have a “buy” rating on the stock.
• 10/31/2025 – Ardelyx had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 10/31/2025 – Ardelyx had its price target raised by analysts at TD Cowen from $9.00 to $10.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Ardelyx had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Ardelyx had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling

In related news, insider Laura A. Williams sold 80,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $6.12, for a total value of $489,600.00. Following the completion of the sale, the insider directly owned 366,322 shares in the company, valued at approximately $2,241,890.64. The trade was a 17.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Raab sold 45,687 shares of the company’s stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $5.93, for a total value of $270,923.91. Following the sale, the chief executive officer owned 1,502,250 shares of the company’s stock, valued at approximately $8,908,342.50. The trade was a 2.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 165,551 shares of company stock valued at $996,917. 4.80% of the stock is owned by company insiders.

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.